Status:
COMPLETED
Consumer Perceptions of Cannabidiol (CBD) Health Claims
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
University of North Carolina, Chapel Hill
Conditions:
Perceptions
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Over 46 million US adults report use of cannabidiol (CBD), primarily to treat medical ailments. The growing CBD market spans the range of products that the US Food and Drug Administration (FDA) regula...
Detailed Description
Cannabidiol (CBD) products have rapidly gained popularity, spanning the retail market with a range of products that the US Food and Drug Administration (FDA) regulates including drugs, dietary supplem...
Eligibility Criteria
Inclusion
- Age 18-65
- US Residents
- Satisfies one of the following categories:
- Current CBD users
- Ever CBD users
- Non-CBD users
- Members of the AmeriSpeak™ panel
Exclusion
- Non-English speakers
- Younger than 18 or older than 65
- Not US residents
- Not members of the AmeriSpeak™ panel
Key Trial Info
Start Date :
October 9 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 20 2023
Estimated Enrollment :
3504 Patients enrolled
Trial Details
Trial ID
NCT06069713
Start Date
October 9 2023
End Date
November 20 2023
Last Update
December 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157